NAREB final meeting in Belgium
NAREB final meeting! Our first European Project is ending after four years contributing to develop new nanotherapeutics.
The company´s main contribution in this Project, Nanotherapeutics for Antibiotics Resistant Emerging Bacterial pathogens, is related to physicochemical characterization of nanodelivery systems.
This is a biological and immunological characterization, both in vitro and in vivo, and biodistribution in order to test the safety of the nanosystems developed and to validate cell targeting.